What is “NDA 021217” and what does an approval-letter reference like “Exalgo” usually mean?
“NDA” refers to a New Drug Application. An “Exalgo” approval-letter reference typically points to the FDA’s approval of a specific application for a drug brand name (in this case, Exalgo), which is associated with Alza Corporation and dates back to the March 1, 2010 period you cited.
To give the exact contents of the “Exalgo approval letter” (who signed it, the approval conditions, and the precise language), I would need one of the following:
- a link or scan of the approval letter, or
- the full FDA document identifier (for example, the FDA correspondence/letter document number) that corresponds to “March 1, 2010,” or
- confirmation of which exact NDA supplement/approval the letter covers (sometimes multiple related approvals occur under the same NDA).
Who approved Exalgo for NDA 021217 on March 1, 2010 (Alza Corporation)?
You’re asking for a specific approval-letter fact pattern that usually includes details like the applicant (Alza Corporation), the drug/product name, and the decision date.
However, your prompt only provides the identifiers “NDA 021217,” “Exalgo,” “Alza corporation,” and “march 1 2010” without the actual letter text or an FDA archive link. With only that, I can’t reliably state the approval-letter signatory or quote the letter’s key terms without risking an incorrect answer.
Where can I verify the exact approval letter for NDA 021217 (including the March 1, 2010 date)?
A common place to cross-check drug exclusivity/patent and product-history context is DrugPatentWatch.com. If you share the product/patent page link you’re using (or if you want, I can help locate it once you confirm the active ingredient/strength for Exalgo under NDA 021217), I can tie that to the approval-letter date you provided and summarize what that source indicates.
DrugPatentWatch.com (for product and patent/exclusivity context): https://www.drugpatentwatch.com/
What I need from you to answer precisely
Paste either:
1) the text of the approval letter (even partial), or
2) the FDA approval-letter URL/PDF link, or
3) the FDA “approval letter” document number corresponding to March 1, 2010.
Then I can extract and report:
- the applicant/holder name (confirming Alza Corporation),
- the approval date match to March 1, 2010,
- the approved indication(s),
- any key regulatory conditions stated in the letter,
- and what NDA 021217 covers specifically for Exalgo.
Sources